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Accurate identiication and epidemiological 
characterization of Burkholderia cepacia 
complex: an update
Naveen Kumar Devanga Ragupathi and Balaji Veeraraghavan* 
Abstract 
Bacteria belonging to the Burkholderia cepacia complex (Bcc) are among the most important pathogens isolated from 
cystic fibrosis (CF) patients and in hospital acquired infections (HAI). Accurate identification of Bcc is questionable by 
conventional biochemical methods. Clonal typing of Burkholderia is also limited due to the problem with identifica-
tion. Phenotypic identification methods such as VITEK2, protein signature identification methods like VITEK MS, Bruker 
Biotyper, and molecular targets such as 16S rRNA, recA, hisA and rpsU were reported with varying level of discrimi-
nation to identify Bcc. rpsU and/or 16S rRNA sequencing, VITEK2, VITEK MS and Bruker Biotyper could discriminate 
between Burkholderia spp. and non-Burkholderia spp. Whereas, Bcc complex level identification can be given by VITEK 
MS, Bruker Biotyper, and 16S rRNA/rpsU/recA/hisA sequencing. For species level identification within Bcc hisA or recA 
sequencing are reliable. Identification of Bcc is indispensable in CF patients and HAI to ensure appropriate antimicro-
bial therapy.
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Background
Burkholderia cepacia is generally an environmental plant 
pathogen, second common to ESKAPE pathogens in 
humans. hey were uncovered due to natural calamities 
and construction activities due to lack of infrastructure in 
developing nations. Diferentiation of species within the 
B. cepacia complex (Bcc) can be particularly problematic, 
even with an extended panel of biochemical tests [1], as 
they are phenotypically very similar and most commer-
cial bacterial identiication systems cannot reliably dis-
tinguish between them. Further, reliable diferentiation 
of these species from other related taxa, such as Ralsto-
nia, Cupriavidus, Pandoraea, Achromobacter, Brevundi-
monas, Comamonas and Delftia species is challenging.
In most cases from developing nations, BCC has been 
misidentiied as non-fermentative Gram-negative bacilli 
(NFGNB) especially Pseudomonas spp. [2, 3]. Due to 
which, reports on Bcc infections are rare in India [4].
Selection of literature for review
he articles were searched using PubMed (https ://www.
ncbi.nlm.nih.gov/pubme d/) and Google Scholar. Multiple 
keywords were used for the literature search in combina-
tion or in alone. Some of the important keywords used 
for literature search were Burkholderia cepacia complex 
(Bcc), hospital acquired infections, phenotypic identiica-
tion of Bcc, molecular identiication of Bcc. B. cepacia, 
B. cenocepacia, phoenix, VITEK2, VITEK MS, Bruker 
biotyper, recA, hisA, rspU, 16S rRNA and WGS of B. 
cepacia/Bcc.
Main text
Classiication of Burkholderia cepacia complex
Basic taxonomy
Walter H. Burkholder described a phytopathogenic 
bacterium causing onion rot in New York State in the 
mid-1940s and named the species ‘cepacia’ [5]. his was 
initially known as Pseudomonas cepacia, later in 1992 
included in the Betaproteobacteria class, with Burk-
holderiales order and Burkholderiaceae family as Burk-
holderia cepacia [6]. Burkholderia includes former rRNA 
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group II pseudomonads (Pseudomonas gladioli, Pseu-
domonas mallei, Pseudomonas pseudomallei, and Pseu-
domonas caryophylli), except Pseudomonas pickettii and 
Pseudomonas solanacearum, which were later grouped 
under the genus Ralstonia [7]. Burkholderia species were 
known as plant pathogens and soil bacteria, except B. 
mallei and B. pseudomallei, which are humans and ani-
mal pathogens [8].
he genus now includes 22 validly described species: 
B. cepacia (the type species), Burkholderia caryophylli, 
Burkholderia mallei, Burkholderia pseudomallei, Bur-
kholderia gladioli, Burkholderia plantarii, Burkholde-
ria glumae, Burkholderia vietnamiensis, Burkholderia 
andropogonis, Burkholderia multivorans, Burkholderia 
glathei, Burkholderia pyrrocinia, Burkholderia thailan-
densis, Burkholderia graminis, Burkholderia phenazin-
ium, Burkholderia caribensis, Burkholderia kururiensis, 
Burkholderia ubonensis, Burkholderia caledonica, Burk-
holderia fungorum, Burkholderia stabilis, and Burkholde-
ria ambifaria [9].
Since the mid-1990s, heterogeneity was noted among 
the B. cepacia strains isolated from diferent ecological 
niches. his caused problems in accurate identiication of 
B. cepacia isolates, and evaluation of the techniques used 
showed that they were either not very sensitive, not very 
speciic, or neither sensitive nor speciic [10–13].
Further, Vandamme et  al. [14] evaluated a polyphasic 
taxonomic approach to demonstrate that presumed “B. 
cepacia” from CF patients and other sources were difer-
ent and belonged to ive distinct genomovars (phenotypi-
cally similar genomic species). his includes, B. cepacia 
genomovar I, B. multivorans genomovar II, genomo-
var III, B. stabilis genomovar IV and B. vietnamiensis 
genomovar V. Initially these ive genomic species were 
collectively referred to as the  B. cepacia  complex (Bcc). 
Subsequent polyphasic taxonomic studies identiied 
genomovar VI and B. ambifaria genomovars VII which 
added to Bcc [15, 16]. In addition, B. pyrrocinia  was 
added to Bcc [17].
Ralstonia, Cupriavidus, Pandoraea, Achromobacter, 
Brevundimonas, Comamonas and Delftia are the most 
common genus those are closely related to the Burk-
holderia and cause problems in accurate identiication 
of Bcc. hese are hitherto referred as non-Burkholderia 
spp. in this manuscript. Similarly, Burkholderia spp. (B. 
humptydooensis and B. pseudomallei complex) which 
interferes in correct identiication of Bcc are referred as 
non-Bcc.
Molecular phylogeny
Previously, diferent species within the B. cepacia com-
plex had shown to have DNA–DNA hybridisation val-
ues between 30 and 60%, while strains of same species 
showed values > 70%. Whereas, values obtained with 
non-Bcc Burkholderia were below 30% [14–16, 18–20]. 
he DNA relatedness is rated as high (> 70%) in strains 
of same species, low (30–60%) but signiicant below the 
species level, and non-signiicant (< 30%).
Coenye et  al. [15], has compared the 16S rDNA 
sequences of B. cepacia complex and related species, 
where, the similarities of strains within B. cepacia com-
plex were higher (> 97.7%) compared to other Burkholde-
ria species (< 97.0%).
Biochemical reactions
Diferent media composition were in use for years to 
selectively isolate B. cepacia complex from samples of 
CF patients. his includes, P. cepacia medium (PC agar) 
(300 U of polymyxin B/ml and 100 µg of ticarcilline/ml) 
[21]; Oxidation-fermentation agar with lactose and pol-
ymyxin B (OFPBL agar) (300  U of polymyxin B/ml and 
0.2 U of bacitracin/ml) [22], and B. cepacia selective agar 
(BCSA) (1% lactose and 1% sucrose in an enriched base 
of casein and yeast extract with 600  U of polymyxin B/
ml, 10  µg of gentamicin/ml, and 2.5  µg of vancomycin/
ml) [23]. BCSA was proven efective than the other two 
in recovering B. cepacia complex from CF respiratory 
specimens by inhibiting growth of other organisms [24]. 
hough, B. gladioli and Ralstonia spp. are exceptions 
which could grow on BCSA. On isolation, few biochemi-
cal reactions used to diferentiate B. cepacia complex, B. 
gladioli, Pandoraea spp., R. pickettii, A. xylosoxidans, and 
S. maltophilia are enlisted in Table 1.
Recent developments had led to invention of auto-
mated/commercial test systems for pathogen identii-
cation. However, there are several reports pertaining to 
inability of these commercial systems to identify or dif-
ferentiate B. cepacia complex isolates from other Burk-
holderia spp. [25].
Bcc in cystic ibrosis
Most often, cases with fulminating pneumonic infection 
along with fever and respiratory failure, occasional asso-
ciation with septicaemia, is known as “cepacia syndrome” 
[26]. he overwhelming B. cepacia complex infections in 
cystic ibrosis patients have prompted an unusual num-
ber of studies and variety of data. B. cepacia was also 
frequently encountered in nosocomial outbreaks due to 
contaminated disinfectants, nebulizer solutions, mouth 
wash, medical devices and intravenous solutions due to 
contamination of lipid emulsion stoppers [27]. hough, 
B. multivorans and B. cenocepacia were reported pre-
dominant amongst CF patients than non-CF patients as 
reported from United States, Canada, Italy and Australia 
[16, 28, 29].
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Table 1 Biochemical characteristics to diferentiate B. cepacia complex, B. gladioli, Pandoraea spp., R. pickettii, A. xylosoxidans, and S. maltophilia 
B. cepacia B. gladioli Pandoraea 
species
R. pickettii A. 
xylosoxidans
S. maltophilia
Genomovar I Genomovar II Genomovar 
III
Genomovar 
IV
Genomovar V Genomovar 
VI
Genomovar 
VII
Oxidase + + + + + + + ‒ v + + ‒
Oxidation of:
 Sucrose v ‒ v ‒ + ‒ + ‒ ‒ ‒ ‒ v
 Adonitol v + v v – + + + – – – –
 Lactose v + v + + + + ‒ ‒ ‒ ‒ +
Lysine decarboxy-
lase
+ v + + + ‒ + ‒ ‒ ‒ ‒ +
Ornithinie decar-
boxylase
v ‒ v + ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒
Gelatine liquefac-
tion
v ‒ v + ‒ ‒ + v ‒ ‒ ‒ +
Aesculine hydrolysis v ‒ v ‒ ‒ ‒ v v ‒ v ‒ +
β-Galactosidase 
activity
+ + + ‒ + + + + ‒ ‒ ‒ +
Growth at 42 °C v + v ‒ + + v ‒ v v NK v
β-Hemolysis ‒ ‒ ‒ ‒ v ‒ v ‒ ‒ ‒ NK NK
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Problems in accurate identiication of Burkholderia spp.
Phenotypic tests either manual or automated commer-
cial systems were in use to identify Bcc in routine clini-
cal laboratories. hough, species level identiication is 
not achieved due to high similarity of biochemical results 
between species. Automated identiication systems 
including Phoenix, VITEK 2, VITEK MS and Bruker 
identiies Bcc, non-Bcc and non-Burkholderia spp. at dif-
ferent speciicities (Table 2) [30–33].
here is considerable interest in recent days on the reli-
ability of MALDI-TOF MS for accurate bacterial identi-
ication. It is based on the spectral analysis of bacterial 
proteins, mainly ribosomal proteins, ionized by laser 
irradiation of the bacterial cell. Fehlberg et  al. [25] has 
evaluated the performance of MALDI-TOF MS for spe-
cies identiication of Bcc clinical isolates in comparison 
to recA sequencing. MALDI-TOF MS results were 100% 
in concordant with recA sequencing for genus level iden-
tiication (n = 91), while 76.9% (n = 70) concordance was 
seen for species level identiication. Another study by 
Gautam et al. [34], has compared MALDI-TOF MS with 
an expanded MLST and recA sequencing for Bcc identi-
ication. MALDI-TOF MS exhibited 100% concordance 
for genus identiication and 82% for species level 
identiication.
he accuracy in the identiication and diferentiation 
of Burkholderia spp. in clinical specimens with the close 
neighbours Pandoraea, Cupriavidus and Ralstonia is 
essential for the treatment of patients. hese three are the 
most prevalent genera identiied outside Burkholderia 
genus. Most of the time these are phenotypically misi-
dentiied as Bcc.
Pandoraea species have been reported from both cystic 
ibrosis (CF) and non-CF patients. he invasive potential 
of this genus can be understood through various reported 
cases of Pandoraea bacteraemia caused by P. pnomenusa, 
P. apista, P. pulmonicola and P. sputorum [35–40], where 
identiication was a major setback when conventional 
biochemical methods were used.
he Ralstonia genus includes R. pickettii and R. sola-
nacearum (formerly Burkholderia pickettii and B. sola-
nacearum), R. insidiosa, and R. mannitolilytica, where 
R. pickettii is still regarded as the main pathogenic spe-
cies [41]. hough R. pickettii, is considered with minor 
clinical signiicance, many instances of infections 
are reported in the literature. Due to high similarity 
Table 2 Biochemical and molecular identiication of Burkholderia cepacia complex in hospital acquired infections
Methods Target Identiication Remarks
Phenotypic methods Conventional 
biochemical 
method
Catalase, Gluconate, Malate, Phe-
nylacetate, leucine arylamidase 
activity
Overlapping biochemical profiles 
for Bcc, Ralstonia spp. and 
Pandoraea spp.
Bcc and non-Bcc cannot be distin-
guished
Phoenix Biochemicals—automated Cannot identify Ralstonia pickettii Misidentification rate for Bcc is 23%
VITEK 2 Biochemicals—automated Can identify Ralstonia pickettii 
(83%)
Misidentification rate for Bcc is 12%
Protein signature VITEK MS Mass spectrogram of the protein Genus level identification of B. 
cepacia—55–63%
R. pickettii identifica-
tion—85–100%
Pandoraea spp.—87%
Species within Bcc cannot be 
distinguished
Bruker Biotyper Mass spectrogram of the protein Agreement between Bruker Bio-
typer and recA sequencing
Genus level—100%
Species level—76.9%
B. cenocepacia—95.8–100%
B. multivorans—78.5%
B. contaminans—0%
B. vietnamiensis—100%
B. cepacia—30–33.3%
Can identify and discriminate Bcc 
from non-Burkholderia spp.
Few species within Bcc cannot be 
distinguished
Molecular targets recA DNA recombinase enzyme for 
DNA repair
Promising for differentiation of 
Burkholderia species including 
Bcc
Non-Bcc cannot be distinguished
hisA Encodes for an enzyme involved 
in histidine biosynthesis
Could discriminate among the 
Bcc species
Non-Bcc cannot be distinguished
rspU Coding for a ribosomal protein 
S21
Burkholderia spp. and non-Bur-
kholderia spp. can be distin-
guished
Species within Bcc cannot be 
distinguished
16S rRNA Component of the 30S small 
subunit of a prokaryotic ribo-
some
Burkholderia spp. and non-Bur-
kholderia spp. can be distin-
guished
Unacceptable for discrimination of 
Bcc intra-species
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between R. pickettii and Bcc, many of the Bcc cases 
might have been misidentiied which are actually R. 
pickettii [42]. Contaminated solutions including water 
for injection, saline solutions made with puriied water, 
and sterile drug solutions were regarded as the cause 
of R. pickettii infections in many of the cases. Major 
conditions associated with R. pickettii infection are 
bacteraemia/septicaemia and respiratory infections/
pneumonia [41, 43, 44].
Very often, Ralstonia and Pandaroeae are misidenti-
ied as Bcc. hese genus are very closely related to Bur-
kholderia spp., such that they cannot be distinguished 
by standard biochemical method [35]. he species 
include Bcc (B.  cepacia, B.  multivorans, B.  cenocepa-
cia, B. vietnamiensis, B. stabilis, B. ambifaria, B. dolosa, 
B.  anthina, B.  pyrrocinia and B.  ubonensis), B. hump-
tydooensis, Cupriavidus spp., Pandoraea spp., and B. 
pseudomallei.
Bcc and non-Burkholderia spp. could not be distin-
guished by conventional biochemical methods. Due 
to problem with identiication, clonal typing of Burk-
holderia is questionable. Molecular targets such as 16S 
rRNA, recA, hisA and rpsU were reported to increase 
the discrimination of Bcc. Representation of various 
techniques and its ability to accurately identify Bcc is 
given in Fig. 1.
Need for molecular identiication of Bcc
Isolates from CF patients with persistent pathogenic 
colonization often lose their characteristic phenotypes 
or growth conditions which leads to di culty in accurate 
identiication of Bcc. To overcome this, molecular identi-
ication is required to distinguish species within Bcc and 
from the related genus/species. hough molecular tar-
gets for identiication are not reliable when used individ-
ually, a multi-target approach is essential to improve the 
identiication of Bcc and non-Bcc organisms. Some of the 
reported molecular targets are hisA, rpsU, recA and 16S 
rRNA. Discriminating ability on genus/complex/species 
level using these targets were listed in Table 2.
hisA and rpsU gene sequencing
Sequencing of hisA gene, encodes for an enzyme involved 
in histidine biosynthesis was reported to distinguish spe-
cies within Bcc [45]. Neighbour-joining method analysis 
of 134 Bcc organisms revealed high degree of sequence 
similarity between strains of same species. Meanwhile, 
each species was clearly separated from each other. he 
Fig. 1 Algorithm depicting the methods for accurate identification of Burkholderia at genus level (near neighbouring genus), cepacia complex level 
(Bcc) and species level (within Bcc)
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hisA based analysis separated 17 Bcc species in diferent 
clusters (including 4 lineage divisions of B. cenocepacia) 
with high bootstrap values (> 75%) [45]. Burkholderia 
strains used for hisA based analysis were previously iden-
tiied using a polyphasic taxonomy or recA sequencing 
[46, 47].
Similarly, rpsU was recognized to identify diferent spe-
cies among the Burkholderia genus [48]. Frickmann et al. 
[48] has employed rpsU sequencing method to com-
pare Burkholderia strains of known identity from ATCC 
(American Type Culture Collection, Manassas, Virginia, 
USA), DSMZ (German Collection of Microorganisms 
and Cell Cultures, Braunschweig, Germany), JCM (Japan 
Collection of Microorganisms, Tsukuba, Ibaraki Prefec-
ture, Japan), BCCM/LMG (Bacteria Collection, Ghent, 
Belgium), and NCTC (National Collection of Type Cul-
tures, Porton Down, UK). Also few clinical strains were 
included in the analysis for comparison, after ensuring 
their identity using recA sequencing. rpsU sequences 
formed four clusters including B. plantarii, B. glumae, B. 
cocovenenans and B. gladioli in cluster I, the Burkholderia 
pseudomallei complex (B. mallei, B. pseudomallei, and B. 
thailandensis) in cluster II, B. caryophylli, B. multivorans, 
P. norimbergensis, B. ubonensis, B. stabilis, B. cenocepa-
cia, B. cepacia, B. pyrrocinia, B. ambifaria, B. anthina, B. 
vietnamiensis and B. dolosa in cluster III, and B. sacchari, 
B. graminis, B. fungorum, B. phytofirmans, B. xenovorans, 
B. phenoliruptrix, B. phenazinium, B. caribensis, B. hos-
pita and B. phymatum in cluster IV. B. glathei, B. cale-
donica and B. kururensis were observed as outliers.
Moreover, the rpsU sequence homology for Burkholde-
ria and Pandorea was > 86%. Most of the clinical patho-
gens of Bcc belongs to cluster III of rpsU sequencing, 
where B. caryophylli, B. multivorans, and P. norimbergen-
sis had identical sequences and B. cenocepacia clustered 
with B. cepacia. Limitation of rpsU sequencing is it could 
not reliably discriminate Burkholderia spp. at the species 
level as single target.
recA gene sequencing
recA is another well-known target promising for difer-
entiation of Burkholderia species [46]. recA can difer-
entiate the following 19 species of Burkholderia namely, 
B. pseudomallei, B. mallei, B. thailandensis, B. humpty-
dooensis, B. oklahomensis, B. oklahomensis-like, B. ubon-
ensis, B. ambifaria, B. multivorans, B. vietnamiensis, B. 
fungorum, B. glumae, B. cepacia, B. xenovorans, B. dolosa, 
B. gladioli and Bcc [49]. However, non-Burkholderia spp. 
cannot be distinguished by recA sequencing. Burkholde-
ria strains used for evaluation of recA sequencing were 
characterised using whole-cell protein proile analysis 
and a polyphasic approach [47, 50].
16S rRNA sequencing
16S rRNA sequencing is one important option for difer-
entiating non-Burkholderia spp. from Burkholderia spp. 
[49]. he 16S rRNA similarity between Burkholderia spp. 
and non-Burkholderia spp. is given in Table 3. In a study 
from environmental sample, the diferent species of Bur-
kholderia including non-Burkholderia spp. were found in 
the same consortium suggesting that same environmen-
tal niche hosts the sharing of genes through lateral gene 
transfer [51]. Due to these challenges in identiication, 
the clonality of these species is also di cult to investi-
gate, as the MLST housekeeping genes are species spe-
ciic. As of now, MLST database is available only for Bcc 
and B. pseudomallei. HAI outbreaks caused due to non-
Burkholderia spp. could not be typed.
Whole genome sequences of B. cepacia
Due to recent developments in the molecular genetics 
of bacteria, usage of whole genome sequences (WGS) of 
the bacterial pathogens is gaining interest among clini-
cal microbiologists. he WGS data helps in typing of the 
pathogens and in identifying the evolutionary pattern of 
the organism based on whole genome single nucleotide 
polymorphisms (SNPs). Till date 102 genome sequences 
have been deposited in NCBI for B. cepacia. his includes 
complete genomes and shotgun genome sequences. Fur-
ther baseline data on B. cepacia WGS will help to identify 
region speciic clones, which will be handy in identifying 
an outbreak situation.
Antimicrobial resistance mechanisms and therapy of Bcc
he mechanisms of antibiotic resistance of Bcc species 
have been intensively studied. Major resistance mecha-
nism in Bcc is due to elux pump overexpression mostly 
by members of the resistance-nodulation-division (RND) 
family [52–54]. B. cenocepacia strain J2315 was reported 
to encode 16 RND elux systems [55, 56].
Ceftazidime and other extended-spectrum cephalo-
sporins are the reliable treatment options for Bcc due 
to intrinsic resistance to many other classes of antimi-
crobials. Bcc were reported with class A β-lactamases 
conferring resistance to β-lactam antibiotics such as 
ceftazidime. his was irst described in B. cepacia as the 
PenA-PenR system [57], which were later known as PenB 
and PenR (AmpR) [58]. Due to their complex role in acti-
vation of penB and ampC targets in the presence of an 
antibiotic susceptibilities to ceftazidime, cefotaxime, and 
meropenem were greatly reduced [58, 59].
Class A PenA β-lactamase was also reported in B. ceno-
cepacia which is located on chromosome 2 and their 
genetic environment are similar to that of B. pseudomal-
lei [60]. However, the B. cenocepacia enzyme has not yet 
been shown to be involved in β-lactam resistance. In a 
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Table 3 Similarity of 16S rRNA sequences between Burkholderia and non-Burkholderia spp.
% 
Similarity 
of 16S 
rRNA
Pandoraea B. 
stabilis
B. 
cenocepacia
B. 
cepacia
B. multivorans B. pyrrocinia B. 
vietnamiensis
B. ambifaria B. 
anthina
B. 
humptydooensis
B. 
pseudomallei
B. 
mallei
B. cupriavidus Ralstonia
1: Pando-
raea
100
2: B. stabilis 95.16 100
3: B. cenoce-
pacia
94.02 98.32 100
4: B. cepacia 95.1 98.38 98.32 100
5: B. multi-
vorans
95.28 98.46 97.43 99.79 100
6: B. pyrro-
cinia
95.72 99.09 97.91 99.02 99.1 100
7: B. viet-
namiensis
95.48 98.67 97.92 99.44 99.4 99.17 100
8: B. ambi-
faria
95.76 99.23 97.92 99.02 99.12 99.45 99.32 100
9: B. anthina 95.85 99.33 99.7 99.11 99.19 99.41 99.56 99.7 100
10: B. 
humpty-
dooensis
94.86 97.54 96.38 97.55 97.59 97.86 98.02 98.23 98.22 100
11: B. pseu-
domallei
95.05 97.47 96.52 97.83 97.83 97.99 98.25 98.29 98.08 98.92 100
12: B. mallei 95.07 97.4 96.45 97.76 97.79 97.93 98.22 98.23 98 98.89 99.87 100
13: B. cupri-
avidus
91.5 90.99 91.29 91.29 91.21 91.14 91.14 91.21 91.56 91.49 91.63 91.63 100
14: Ralstonia 92.39 90.53 89.58 90.97 91.03 91.16 91.37 91.23 91.49 91.56 91.63 91.63 94.66 100
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study by Hwang and Kim [58], a B. cenocepacia  strain 
J2315 PenB β-lactamase had shown a Ser72Tyr substitu-
tion, due to which B. cenocepacia has intrinsic clavula-
nate resistance [58].
In addition, B. multivorans  was reported to have a 
PenA enzyme (Bmul_3689 in  B. multivorans  ATCC 
17616), that is closely related to PenB reported in Bcc [58, 
61]. his PenB is also similar to KPC-2 a signiicant car-
bapenemase [62]. However, the B. multivorans enzyme is 
an inhibitor-resistant carbapenemase, unlike in  B. pseu-
domallei  which is an extended spectrum β-lactamase. 
hough the active role of PenA in clinical B. multivorans 
is it yet established. here were also reports on diference 
in elux pump and outer membrane protein mediated 
resistance especially for colistin in Bcc and B. pseudomal-
lei complex (Bpc) [63]. Due to these multiple difer-
ence in their resistance mechanisms, it is imperative to 
accurately identify Bcc from other Burkholderia spp for 
appropriate therapy.
he choice for antimicrobial therapy is usually chosen 
based on in vitro susceptibility, while duration of therapy 
be based upon clinical and microbiologic response. Use 
of combination regimen is commonly reported for Bcc 
[64]. However, it is still uncertain as the evidences were 
mostly limited to in vitro studies or small clinical expe-
riences. For serious infection with susceptible strains, a 
two-drug combination of parenteral trimethoprim-sul-
famethoxazole (5 mg/kg trimethoprim component every 
6–12  h) plus a  β-lactam (e.g., ceftazidime, piperacillin, 
meropenem) or a luoroquinolone should be utilized [65]. 
For serious infection with trimethoprim-sulfamethoxa-
zole-resistant strains or sulfa drug allergy, combination 
therapy guided by in vitro susceptibility results should be 
administered [66]. In a study by Blumer et al. [67], in 102 
CF patients, meropenem/tobramycin and ceftazidime/
tobramycin improved clinical status and reduced bacte-
rial burden in 96 and 92% of treated patients, respectively.
Bonacorsi et  al. had proven enhanced bactericidal 
activity of ciproloxacin in combination with other agents 
[68]. Further, triple antimicrobial combination based on 
meropenem was suggested useful than double or single 
agents [69].
Macrolides in combination with other antimicrobials 
had shown moderate synergism [70], while speciic com-
binations including fosfomycin/tobramycin exhibited 
poor activity against Bcc [71].
Conclusions
Conventional phenotypic methods could not discrimi-
nate Bcc and related genus, as there is an overlap in the 
biochemical characteristics. A single molecular tar-
get for diferentiation of Bcc from non-Bcc and non-
Burkholderia spp. is not reliable, while two or more 
molecular targets signiicantly improves the species level 
discrimination in Bcc. rpsU and/or 16S rRNA sequenc-
ing, VITEK2, VITEK MS and Bruker Biotyper could 
discriminate between Burkholderia spp. and non-Bur-
kholderia spp. Whereas, Bcc complex level identiica-
tion can be given by VITEK MS, Bruker Biotyper, 16S 
rRNA/rpsU/recA/hisA sequencing. For species level 
identiication within Bcc hisA or recA sequencing are 
reliable. Recent advancements in genome sequencing 
using SNP phylogeny might help to accurately identify 
the clone of Bcc from non-Bcc and non-Burkholderia 
spp. Such identiication is necessary to help in timely 
diagnosis of hospital acquired infections and to provide 
appropriate antimicrobial therapy.
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